CN105708914A - Traditional Chinese medicine composition for treating prostatitis - Google Patents

Traditional Chinese medicine composition for treating prostatitis Download PDF

Info

Publication number
CN105708914A
CN105708914A CN201410727004.XA CN201410727004A CN105708914A CN 105708914 A CN105708914 A CN 105708914A CN 201410727004 A CN201410727004 A CN 201410727004A CN 105708914 A CN105708914 A CN 105708914A
Authority
CN
China
Prior art keywords
weight
chinese medicine
medicine composition
parts
prostatitis
Prior art date
Application number
CN201410727004.XA
Other languages
Chinese (zh)
Inventor
田仁周
Original Assignee
田仁周
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 田仁周 filed Critical 田仁周
Priority to CN201410727004.XA priority Critical patent/CN105708914A/en
Publication of CN105708914A publication Critical patent/CN105708914A/en

Links

Abstract

The invention discloses a traditional Chinese medicine composition for treating prostatitis. The traditional Chinese medicine composition is prepared from 10-25 parts by weight of banksia rose, 1-8 parts by weight of fleece-flower root, 10-20 parts by weight of coptis root, 10-25 parts by weight of root of wilford swallowwort, 2-15 parts by weight of Hypericum attenuatum Choisy., 1-10 parts by weight of ricepaper pith and 3-7 mole crickets. The traditional Chinese medicine composition has simple components with natural sources, has good prostatitis treatment effects, has a cure rate of 90%, is stable, has no obvious toxic or side effect, can be processed to form a drug through simple processes and has a low processing cost.

Description

One treats prostatitic Chinese medicine composition
Technical field
The present invention relates to technical field of Chinese medicines, particularly relate to one and treat prostatitic Chinese medicine composition.
Background technology
Prostatitis is always up one of andrology and urological subject matter, and the sickness rate in crowd changes greatly, and each result of study is also not quite similar.The health statistics at International Health center shows, 1977-1978 prostatitis sickness rate is about 25%;The male of 35%~50% can in life certain time be subject to the urology department outpatient service of the report such as the prostatitic Pavone of impact Italy and have the patient of nearly 18.9% to go to a doctor because prostatitis clinical symptoms occurs repeatedly.
In China, prostatitis accounts for the 1/3 of urinary system andrology out-patient sum.Prostatitis is the common disease of man, produces to have a strong impact on to patient's physical and mental health, and sickness rate has increase trend, be worth further investigation.Wherein, chronic prostatitis is the modal a kind of disease of Urology Surgery, and chronic prostatitis is generally divided into three types: chronic bacterial prostatitis, nonbacterial prostatitis and prostatodynia by the method relatively generally acknowledged.Wherein chronic nonbacterial prostatitis accounts for 64%, other causes of disease are still unclear, it is on the basis to chronic nonbacterial prostatitis literature review, think the cause of disease to chronic nonbacterial prostatitis, pathophysiological mechanism understanding not enough, therefore at present also not up to comparatively ideal therapeutic effect.Chronic nonbacterial prostatitis accounts for the prostatitic overwhelming majority, at present its cause of disease, epidemiology, diagnosis, treatment all there is certain progress, but owing to its etiology and pathogenesis not yet illustrates completely, western medicine often lacks thoroughly effective medicine, cause primary disease cure rate low, relapse rate is high, hence it is evident that affect patients ' life quality.The treatment of primary disease be have accumulated rich experience by Chinese medicine in long-term clinical practice, it is shown that the obvious characteristic of Chinese medicine primary disease and advantage.
Summary of the invention
It is an object of the invention to provide one and treat prostatitic Chinese medicine composition, it can heat-clearing and toxic substances removing, effectively treat prostatitis, and evident in efficacy, without obvious toxic-side effects.
The technical solution used in the present invention is as follows:
One treats prostatitic Chinese medicine composition, and it includes the composition of following quality proportioning:
Radix Aucklandiae 10-25 weight portion, Radix Polygoni Multiflori 1-8 weight portion, Rhizoma Coptidis 10-20 weight portion, Radix cynanchi wilfordii 10-25 weight portion, Herba hyperici attenuati 2-15 weight portion, Medulla Tetrapanacis 1-10 weight portion, Gryllotalpa 3~7.
Preferably, said composition includes: Radix Aucklandiae 10-20 weight portion, Radix Polygoni Multiflori 2-5 weight portion, Rhizoma Coptidis 12-20 weight portion, Radix cynanchi wilfordii 10-20 weight portion, Herba hyperici attenuati 5-8 weight portion, Medulla Tetrapanacis 3-8 weight portion, and Gryllotalpa 3-5 is only.
It is highly preferred that said composition includes: the Radix Aucklandiae 15 weight portion, Radix Polygoni Multiflori 2-5 weight portion, Rhizoma Coptidis 15 weight portion, Radix cynanchi wilfordii 15 weight portion, Herba hyperici attenuati 5 weight portion, Rhizoma Smilacis hypoglaucae 3-8 weight portion, Gryllotalpa 5.
The heretofore described Radix Aucklandiae is the root of Compositae thing Radix Aucklandiae AuckiandialappaDecne., has promoting the circulation of QI to relieve pain, effect of strengthening the spleen to promote digestion.
Heretofore described Radix Polygoni Multiflori is the dried root of polygonum multiflorum thunb PolygonummultiflorumThunb., has tonifying liver, kidney tonifying, nourishes blood, the effect dispeled the wind.
Heretofore described Rhizoma Coptidis is the dry rhizome of ranunculaceae plant Rhizoma Coptidis CoptischinensisFranch., Coptis deltoidea C.Y.Cheng et Hsiao CoptisdeltoideaC.Y.ChengetHsiao or Coptis Teeta Wall CoptisteetaWall..There is heat clearing and damp drying, effect of eliminating fire and detoxication.
Heretofore described Radix cynanchi wilfordii is the tuber of trailing plants section plant cynanchum auriculatum Royle, has yin nourishing qi-restoratives, effect of strengthening the spleen to promote digestion.
Heretofore described Herba hyperici attenuati is the herb of Garcinia maingayii Herba hyperici attenuati, has cooling blood for hemostasis;Promoting blood circulation and stopping pain;Effect of removing toxic substances and promoting subsidence of swelling.
Heretofore described Medulla Tetrapanacis is the dry stem pith of Araliaceae rice-paper plant Tetrapanaxpapyriferus (Hook.) K.Koch.There is effect of promoting diuresis to eliminate damp pathogen, inducing diuresis for treating stranguria syndrome.
Heretofore described Gryllotalpa is the dry Scorpio of Gryllotalpidae insecticide Gryllotalpa, has effect of diuretic, relieving constipation.
The preparation method of Chinese medicine composition of the present invention is as follows:
The raw medicinal material of the above-mentioned weight in compositions is made powdered, then mixes, make powder.The boiled water adding 50-80 weight portion when taking soaks.
Conventionally the compositions of the present invention can also be made other preparations being suitable for, for instance granule, capsule etc..
The using method of the medicament of the present invention is preferably as follows:
Described medicament is that powder boiled water is taken after mixing it with water, and a course for the treatment of is three days, and every day is administered orally 2 times (ante cibum), about 6-10g (dry powder) every time, and brews with the boiled water of 50-80g.Need alleviating alcohol addiction during taking this medicament, light food (being practically free of condiment) should be eaten, and defecation unobstructed after namely must withdraw this medicament.
The feature of the present invention is as follows:
Present component is simple, and sky, source becomes, and treatment prostatitis is respond well, stable, has no obvious toxic-side effects, is made into that medicament technological operation is easy, cost is low.
Detailed description of the invention
Embodiment 1: take Radix Aucklandiae 15g, Radix Polygoni Multiflori 2g, Rhizoma Coptidis 15g, Radix cynanchi wilfordii 15g, Herba hyperici attenuati 5g, Medulla Tetrapanacis 3g, Gryllotalpa 5.Above raw medicinal material mixes after all making powdered, has only to add boiled water afterwards and soaks.Being be administered orally ante cibum when taking, one day oral twice, get it filled powder 6-10g every time, and brews with the boiled water of 50-60g;Need to take continuously three days is a course for the treatment of.
Embodiment 2: take Radix Aucklandiae 15g, Radix Polygoni Multiflori 5g, Rhizoma Coptidis 10g, Radix cynanchi wilfordii 15g, Herba hyperici attenuati 5g, Medulla Tetrapanacis 8g, Gryllotalpa 5.Above raw medicinal material mixes after all making powdered, has only to add boiled water afterwards and soaks.It is be administered orally ante cibum when taking, one day oral twice, takes and want powder 6-10g, and brew with the boiled water of 50-60g;Need to take continuously three days is a course for the treatment of.
In order to test the therapeutic effect of Chinese medicine composition of the present invention, using the medicament of above-described embodiment 1 or 2, altogether treatment is diagnosed as prostatitis male patient totally 42 example clinically, every three days courses for the treatment of, 1~10 course for the treatment of of general treatment.After treatment, various pain symptoms disappear, the normal person that urinates is evaluated as healing, and result cures 38 examples, and cure rate is more than 90%.
Some cases
Clinical case 1, field, man, 60 years old, trike acute prostatitis 1 month, take the prostatic medicine for the treatment of (QIANLIEKANG, SANJIN PIAN etc.) all inefficacies before, after taking one course for the treatment of of inventive formulation by the medicine in the embodiment of the present invention 2 and method, various pain symptoms disappear, urinate normal, do not recur so far.
Clinical case 2, field so-and-so, man, 80 years old, trike acute prostatitis 1 month, hospitalize one month (include taking medicine, give up scorching pin, intubate) inefficacy (remove after intubating cannot normal voiding), after taking one course for the treatment of of inventive formulation by the medicine in the embodiment of the present invention 2 and method, various pain symptoms disappear, urinate normal, do not recur so far.
Clinical case 3, dream, man, 82 years old, trike acute prostatitis 20 days, so-and-so is the same with field in case 2, hospitalize two months (include taking medicine, give up scorching pin, intubate) inefficacy (remove after intubating cannot normal voiding), after taking one course for the treatment of of inventive formulation by the medicine in the embodiment of the present invention 2 and method, various pain symptoms disappear, urinate normal, do not recur so far.
Clinical case 4, field, man, 73 years old, suffer from chronic prostatitis 3 years, dysuria, frequent micturition, dysurea etc., eat the equal inefficacy of medicine that various hospital opens, afterwards for a long time, it is taken 7 course for the treatment of (about 20 days) various pain symptoms afterwards disappearances of inventive formulation according to by the medicine in the embodiment of the present invention 1 and method, urinates normally, does not recur so far.

Claims (4)

1. treat prostatitic Chinese medicine composition for one kind, it is characterised in that said composition includes: Radix Aucklandiae 10-25 weight portion, Radix Polygoni Multiflori 1-8 weight portion, Rhizoma Coptidis 10-20 weight portion, Radix cynanchi wilfordii 10-25 weight portion, Herba hyperici attenuati 2-15 weight portion, Medulla Tetrapanacis 1-10 weight portion, Gryllotalpa 3-7 is only.
2. Chinese medicine composition according to claim 1, it is characterised in that said composition includes: Radix Aucklandiae 10-20 weight portion, Radix Polygoni Multiflori 2-5 weight portion, Rhizoma Coptidis 12-20 weight portion, Radix cynanchi wilfordii 10~20 weight portion, Herba hyperici attenuati 5-8 weight portion, Medulla Tetrapanacis 3-8 weight portion, Gryllotalpa 3-5 is only.
3. Chinese medicine composition according to claim 2, it is characterised in that: said composition includes: the Radix Aucklandiae 15 weight portion, Radix Polygoni Multiflori 2-5 weight portion, Rhizoma Coptidis 15 weight portion, Radix cynanchi wilfordii 15 weight portion, Herba hyperici attenuati 5 weight portion, Medulla Tetrapanacis 3-8 weight portion, Gryllotalpa 5.
4. the preparation method of the Chinese medicine composition according to any one of claim 1-3, it is characterised in that: the raw medicinal material of described weight proportion is made powdered, mixing, make powder.
CN201410727004.XA 2014-12-03 2014-12-03 Traditional Chinese medicine composition for treating prostatitis CN105708914A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410727004.XA CN105708914A (en) 2014-12-03 2014-12-03 Traditional Chinese medicine composition for treating prostatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410727004.XA CN105708914A (en) 2014-12-03 2014-12-03 Traditional Chinese medicine composition for treating prostatitis

Publications (1)

Publication Number Publication Date
CN105708914A true CN105708914A (en) 2016-06-29

Family

ID=56142832

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410727004.XA CN105708914A (en) 2014-12-03 2014-12-03 Traditional Chinese medicine composition for treating prostatitis

Country Status (1)

Country Link
CN (1) CN105708914A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110251647A (en) * 2019-06-28 2019-09-20 四川省一直牛健康管理有限公司 The fever paste for treating prostate and preparation method thereof of a fragrant plant compatibility

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745808A (en) * 2004-09-09 2006-03-15 鲁南制药集团股份有限公司 Chinese medicinal composition for treating chronic prostate and its preparation
CN101284065A (en) * 2007-04-13 2008-10-15 广州中医药大学第二附属医院 Chinese medicinal composition for treating the prostatitis and preparation method thereof
CN102138992A (en) * 2010-11-18 2011-08-03 北京绿源求证科技发展有限责任公司 Traditional Chinese medicine for treating benign prostatic hyperplasia
CN103223052A (en) * 2013-04-27 2013-07-31 陈晖� Traditional Chinese medicine used for treating prostatitis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1745808A (en) * 2004-09-09 2006-03-15 鲁南制药集团股份有限公司 Chinese medicinal composition for treating chronic prostate and its preparation
CN101284065A (en) * 2007-04-13 2008-10-15 广州中医药大学第二附属医院 Chinese medicinal composition for treating the prostatitis and preparation method thereof
CN102138992A (en) * 2010-11-18 2011-08-03 北京绿源求证科技发展有限责任公司 Traditional Chinese medicine for treating benign prostatic hyperplasia
CN103223052A (en) * 2013-04-27 2013-07-31 陈晖� Traditional Chinese medicine used for treating prostatitis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110251647A (en) * 2019-06-28 2019-09-20 四川省一直牛健康管理有限公司 The fever paste for treating prostate and preparation method thereof of a fragrant plant compatibility

Similar Documents

Publication Publication Date Title
Bi et al. Efficacy and safety of herbal medicines in treating gastric ulcer: a review
CN101129817B (en) Chinese medicine formulation for treating hypertension and method of producing the same
CN103463528B (en) Traditional Chinese medicine composition for treating chronic eczema
Gürocak et al. Consumption of historical and current phytotherapeutic agents for urolithiasis: a critical review
CN100428946C (en) Medicine for preventing and controlling chicken infectious fabricius bursa disease
CN102988656B (en) Traditional Chinese medicine composition for treating acute pancreatitis
CN102512611B (en) Traditional Chinese medicine for treating recurrent oral ulcer and preparation method
CN104338062A (en) Chinese medicinal preparation for treating stomachache and diarrhea
CN102008612B (en) Medicament for treating empyrosis and preparation method thereof
CN103990081A (en) Traditional Chinese medicine composition and application thereof in preparation of medicine for treating infant jaundice
CN104306514A (en) Traditional Chinese medicine spray and preparation method thereof
CN100443112C (en) Medicine for treating gout and gout arthritis
CN101167976B (en) Gastrosis-treating medicine
CN102293900B (en) Chinese medicine for treating infantile diarrhea
CN104758825A (en) Traditional Chinese medicine composition for treating amenorrhea
CN102114197A (en) Traditional Chinese medicine oral decoction for treating influenza
CN104771707A (en) Traditional Chinese medicine composition for treating chronic gastritis
CN103720996A (en) Traditional Chinese medicinal composition for treating dysmenorrhea
CN103417946A (en) Drug for treatment of urinary calculus
CN101011544A (en) Gout rapid recovery pill(capsule) and preparation technique thereof
CN102488743B (en) Chinese traditional medicine composition, preparation method thereof and Chinese traditional medicine preparation
CN100512860C (en) Medicine for preventing and controlling chicken infectious laryngotracheitis
CN103830674B (en) One treats lipomatous pharmaceutical composition and preparation method and purposes
CN103550687A (en) Traditional Chinese medicine (TCM) composition for treating deficiency of liver-yin and kidney-yin
CN102406766B (en) Traditional Chinese medicine composition for treating bone fracture and application thereof

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160629

RJ01 Rejection of invention patent application after publication